Revenue Breakdown
Composition ()
No data
Revenue Streams
Clearpoint Neuro Inc (CLPT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Products: Functional neurosurgery, accounting for 37.2% of total sales, equivalent to $3.43M. Other significant revenue streams include Services: Biologics and drug delivery and Products: Biologics and drug delivery. Understanding this composition is critical for investors evaluating how CLPT navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Clearpoint Neuro Inc maintains a gross margin of 63.20%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -59.54%, while the net margin is -66.48%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CLPT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CLPT competes directly with industry leaders such as MLAB and CERS. With a market capitalization of $384.65M, it holds a significant position in the sector. When comparing efficiency, CLPT's gross margin of 63.20% stands against MLAB's 61.46% and CERS's 59.23%. Such benchmarking helps identify whether Clearpoint Neuro Inc is trading at a premium or discount relative to its financial performance.
